AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1981, the company has established itself as a leader in developing innovative therapies primarily focused on women's health, maternal health, and supportive care. With a strong presence in North America and expanding operations in international markets, AMAG is dedicated to addressing unmet medical needs. The company’s core products, including treatments for iron deficiency anaemia and preterm labour, are distinguished by their commitment to safety and efficacy. AMAG's notable achievements include a robust pipeline of therapies that leverage cutting-edge research and development. As a trusted name in the biopharmaceutical sector, AMAG Pharmaceuticals continues to enhance patient outcomes and solidify its market position through strategic partnerships and a focus on innovation.
DitchCarbon Score
How does AMAG Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
AMAG Pharmaceuticals, Inc.'s score of 26 is lower than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
AMAG Pharmaceuticals, Inc.'s reported carbon emissions
In 2022, AMAG Pharmaceuticals, Inc. reported specific CO2 emissions of approximately 165,000 kg CO2e from Scope 1 and 2 sources. This marks a slight decrease from 2021, where emissions were about 168,000 kg CO2e. The company has not disclosed any Scope 3 emissions data for these years. Historically, in 2019, AMAG reported Scope 1 emissions of about 104,400,000 kg CO2e and Scope 3 emissions of approximately 1,200,000,000 kg CO2e. The absence of Scope 2 emissions indicates a focus on direct emissions and those associated with energy consumption. Despite these figures, AMAG has not set specific reduction targets or made formal climate pledges, which may limit their commitment to addressing climate change. The company’s emissions data reflects a need for enhanced transparency and proactive measures in their climate strategy.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2017 | 2018 | 2019 | |
|---|---|---|---|
| Scope 1 | 104,400,000 | 000,000,000 | 000,000,000 |
| Scope 2 | - | - | - |
| Scope 3 | - | - | 0,000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
AMAG Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
